View printer-friendly version

Download PDF

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern

ROCKVILLE, Md.–(BUSINESS WIRE)–May. 19, 2009– Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday, May 21, 2009 beginning at 10:00 am Eastern Time at the Crowne Plaza Hotel, 3 Research Court, Rockville, MD, 20850.

At the annual meeting, stockholders will consider and vote on the following matters:

1. the election of Daniel J. Abdun-Nabi and Dr. Sue Bailey to serve as Class III directors, each for a term of three years;
2. the approval of the company’s Amended and Restated 2006 Stock Incentive Plan, which is proposed primarily for, among other purposes, increasing the number of shares authorized for issuance under our 2006 Stock Incentive Plan by 3,900,000 shares and extending the term of the plan from December 31, 2009 to December 31, 2019; and
3. the ratification of the selection by the audit committee of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2009.

Stockholders also will consider and vote on any other matters as may properly come before the annual meeting or any adjournment or postponement thereof. The company’s board of directors has no knowledge of any other matters which may come before the meeting.

Stockholders of record at the close of business on March 27, 2009 are entitled to notice of, and to vote at, the annual meeting or any adjournment or postponement thereof.

If you plan to attend the meeting, please bring photo identification for admission. Also, if your shares are held in the name of a broker, bank or other nominee, please bring with you a proxy, letter or account statement (or copy thereof) from your broker, bank or nominee confirming your ownership of Emergent BioSolutions stock so that you can be admitted to the meeting. Also, if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a broker’s proxy card issued in your name.

Interested parties may listen to the Annual Meeting via conference call by dialing either 866/314-5232 in the U.S. or 617/213-8052 outside the U.S. No passcode is required for the live call. Interested parties may also access a webcast of the Annual Meeting by visiting the Emergent BioSolutions website at www.emergentbiosolutions.com.

A replay of the teleconference will be available approximately one hour following the conclusion of the call by dialing 888/286-8010 or 617/801-6888 and using the passcode 73054208. The replay will be available through July 28. In addition, the webcast will be archived on the company’s website, www.emergentbiosolutions.com, under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the timing of, and the potential for successful outcomes resulting from future product development efforts and our ability to obtain additional funding from the U.S. government, our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; and other factors identified in the company’s quarterly report on Form 10-Q for the period ended March 31, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 

Source: Emergent BioSolutions Inc.